Referral And Management Of Metachromatic Leukodystrophy (MLD)

Prof. Krageloh-Mann begins by reviewing the three clinical subtypes of MLD�late infantile, juvenile, and adult�and explains their distinct progression patterns. The hallmark of MLD is a phase of normal development followed by subtle stagnation, which may precede a rapid and devastating neurological decline. Early signs can include delays in motor milestones, instability when walking, cognitive regression, or even subtle symptoms such as strabismus. These are often dismissed or misattributed to common developmental variations, leading to diagnostic delays. The case study of a girl with late infantile MLD illustrates the typical trajectory: after reaching early motor milestones on time, she began to show stagnation at 10 months and progressive decline by 18 months. Her case underscores how easily early symptoms can be overlooked and highlights the need for increased awareness among clinicians. Once diagnosed, she experienced a rapid functional decline, entering a near vegetative state within a short timeframe and surviving in this condition for several years. Prof. Kr_geloh-Mann emphasizes that early recognition�during the stagnation phase�is critical, especially as emerging treatments like gene therapy and stem cell transplantation are only effective in early stages. She also addresses the psychosocial burden on families, identifying two particularly distressing periods: the pre-diagnostic phase, when something is clearly wrong but undiagnosed, and the prolonged end-stage, where the child is severely disabled. The webinar outlines essential elements of supportive care, including gastrostomy, spasticity management (e.g., vigabatrin), and psychological support for families. Prof. Kr_geloh-Mann also discusses diagnostic pitfalls and common misdiagnoses such as Guillain-Barr� syndrome, ADHD, or developmental disorders, especially when CSF protein is elevated or peripheral neuropathy is evident. The session concludes by urging pediatricians to recognize children "falling off" their expected developmental paths and to initiate prompt metabolic testing. Enzyme assays and genetic testing remain central to diagnosis, and early MRI findings�especially involving the corpus callosum�should not be underestimated.